Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Dec 27, 2025; 17(12): 110993
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110993

Full Size Figure Download Figure

Figure 2 Toxicity of patients in the study. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase.

Citation: Khosla D, Gade VKV, Kapoor R, Singh G, Singh R, Taneja S, Premkumar M, Kalra N, De A, Bhujade H, Verma N, Duseja A, Gupta R. Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis. World J Hepatol 2025; 17(12): 110993
URL: https://www.wjgnet.com/1948-5182/full/v17/i12/110993.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i12.110993

Khosla D, Gade VKV, Kapoor R, Singh G, Singh R, Taneja S, Premkumar M, Kalra N, De A, Bhujade H, Verma N, Duseja A, Gupta R. Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis. World J Hepatol 2025; 17(12): 110993 [PMID: 41479502 DOI: 10.4254/wjh.v17.i12.110993]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.